Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
A | BPS-3 | 5GL9 | 1.50 | 2017-02-15 | A0A2Z4SUB5 | 27827433 | 10.1038/SREP36527 | pdb | GOL | P 21 21 2 | 75.933 81.637 36.834 ♦ 90.00 90.00 90.00 | 4 | |
A | BPS-3 | 5GLA | 1.50 | 2017-02-15 | A0A2Z4SUB5 | 27827433 | 10.1038/SREP36527 | pdb | P 1 21 1 | 35.031 92.551 68.866 ♦ 90.00 92.61 90.00 | 4 | ||
A | BPS-3 | 5GLB | 1.60 | 2017-02-15 | A0A2Z4SUB5 | 27827433 | 10.1038/SREP36527 | pdb | *CB4 | P 21 21 2 | 70.059 92.881 34.993 ♦ 90.00 90.00 90.00 | 4 | |
A | BPS-3 | 5GLC | 1.60 | 2017-02-15 | A0A2Z4SUB5 | 27827433 | 10.1038/SREP36527 | pdb | P 21 21 2 | 69.486 97.242 34.004 ♦ 90.00 90.00 90.00 | 4 | ||
A | BPS-3 | 5GLD | 1.70 | 2017-02-15 | A0A2Z4SUB5 | 27827433 | 10.1038/SREP36527 | pdb | *CB4 | P 21 21 2 | 70.269 97.448 34.222 ♦ 90.00 90.00 90.00 | 4 | |
A | BPS-3 | 6AFM | 1.30 | 2020-01-15 | A0A2Z4SUB5 | pdb | C74Y | P 21 21 21 | 38.477 52.981 122.731 ♦ 90.00 90.00 90.00 | 4 | |||
A | BPS-3 | 6AFN | 1.40 | 2020-01-15 | A0A2Z4SUB5 | pdb | C74Y | *CB4 GOL | P 21 21 21 | 38.660 53.238 122.981 ♦ 90.00 90.00 90.00 | 4 | ||
A | BPS-3 | 6AFO | 1.40 | 2020-01-15 | A0A2Z4SUB5 | pdb | N141D | P 1 21 1 | 34.986 92.723 68.878 ♦ 90.00 92.72 90.00 | 4 | |||
A | BPS-3 | 6AFP | 1.40 | 2020-01-15 | A0A2Z4SUB5 | pdb | N141D | *CB4 ACT | P 1 21 1 | 34.883 92.393 68.841 ♦ 90.00 94.27 90.00 | 4 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: January 08, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database is funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu